Cognition Therapeutics
Clinical-stage neuroscience company developing oral small-molecule therapeutics designed to protect synapses from toxic protein oligomers in neurodegenerative diseases. The lead investigational candidate is an oral small molecule under clinical development for Alzheimer’s disease and dementia with Lewy bodies. The company advances programs through preclinical research, biomarker-driven clinical studies, CMC/process development, and regulatory interactions.
Industries
Nr. of Employees
small (1-50)
Patents
Isoindoline compositions and methods for treating neurodegenerative disease
US-12466795-B2
View DetailsIsoindoline compositions and methods for treating neurodegenerative disease
US-11691947-B2
View DetailsIsoindoline compositions and methods for treating neurodegenerative disease
US-10611728-B2
View DetailsIsoindoline compositions and methods for treating neurodegenerative disease
US-10207991-B2
View Details
Isoindoline compositions and methods for treating neurodegenerative disease
US-12466795-B2
View DetailsIsoindoline compositions and methods for treating neurodegenerative disease
US-11691947-B2
View DetailsIsoindoline compositions and methods for treating neurodegenerative disease
US-10611728-B2
View DetailsIsoindoline compositions and methods for treating neurodegenerative disease
US-10207991-B2
View DetailsProducts
Zervimesine (CT1812)
Investigational oral small-molecule therapeutic candidate designed to prevent toxic protein oligomers from binding to neuronal synapses with the goal of protecting synaptic integrity and function in neurodegenerative diseases.
Zervimesine
An investigational, small-molecule oral therapy designed to prevent toxic protein oligomers from binding to neurons via the sigma-2 receptor.
CT1812
Lead drug candidate for the treatment of adults with early, mild, and moderate Alzheimer's disease, acting as a sigma-2 (sigma-2) receptor modulator to target amyloid-beta biology and synaptic activity.
CT2074
An investigational sigma-2 receptor modulator studied for neuroprotective effects in models of neurodegeneration and ocular conditions.
Zervimesine (CT1812)
Investigational oral small-molecule therapeutic candidate designed to prevent toxic protein oligomers from binding to neuronal synapses with the goal of protecting synaptic integrity and function in neurodegenerative diseases.
Zervimesine
An investigational, small-molecule oral therapy designed to prevent toxic protein oligomers from binding to neurons via the sigma-2 receptor.
CT1812
Lead drug candidate for the treatment of adults with early, mild, and moderate Alzheimer's disease, acting as a sigma-2 (sigma-2) receptor modulator to target amyloid-beta biology and synaptic activity.
CT2074
An investigational sigma-2 receptor modulator studied for neuroprotective effects in models of neurodegeneration and ocular conditions.
Expertise Areas
- Clinical trial management for neurodegenerative diseases
- Biomarker-driven patient selection and biomarker assay development
- Small-molecule drug discovery and medicinal chemistry
- Chemistry, Manufacturing and Controls (CMC) and process development
Key Technologies
- Oral small-molecule therapeutics
- Sigma-2 receptor targeting
- Disease-relevant high-throughput screening platforms
- Biomarker assays for synaptic density and target engagement
News & Updates
Press release announcing appointment of a chief medical officer and summarizing the company's clinical-stage focus and lead candidate development. Includes mention of Fast Track designation and NIH grant support for clinical studies.
News item summarizing clinical proof-of-concept findings for the investigational small-molecule candidate in Alzheimer’s disease.
News headline reporting a Phase 2 study outcome related to geographic atrophy in dry age-related macular degeneration.
Press release announcing appointment of a chief medical officer and summarizing the company's clinical-stage focus and lead candidate development. Includes mention of Fast Track designation and NIH grant support for clinical studies.
News item summarizing clinical proof-of-concept findings for the investigational small-molecule candidate in Alzheimer’s disease.
News headline reporting a Phase 2 study outcome related to geographic atrophy in dry age-related macular degeneration.